PURPOSE OF REVIEW: Inflammatory breast cancer is a highly aggressive variant of locally advanced breast cancer that carries a significantly worse prognosis. The purpose of this review is to highlight recent advances in the molecular modus operandi of this particular form of breast cancer. RECENT FINDINGS: Studies on tumor cell emboli, E-cadherin, chemokine receptors, steroid hormone receptor, angiogenesis, lymphangiogenesis and gene expression all suggest significant differences with noninflammatory breast cancer and are clearly in line with a different pathogenesis of the condition. SUMMARY: This comprehensive review will hopefully allow for better treatment modalities with targeted approaches as suggested by the early data on anti-vascular endothelial growth factor treatment in inflammatory breast cancer.
PURPOSE OF REVIEW: Inflammatory breast cancer is a highly aggressive variant of locally advanced breast cancer that carries a significantly worse prognosis. The purpose of this review is to highlight recent advances in the molecular modus operandi of this particular form of breast cancer. RECENT FINDINGS: Studies on tumor cell emboli, E-cadherin, chemokine receptors, steroid hormone receptor, angiogenesis, lymphangiogenesis and gene expression all suggest significant differences with noninflammatory breast cancer and are clearly in line with a different pathogenesis of the condition. SUMMARY: This comprehensive review will hopefully allow for better treatment modalities with targeted approaches as suggested by the early data on anti-vascular endothelial growth factor treatment in inflammatory breast cancer.
Authors: Selin Carkaci; Beatriz E Adrada; Eric Rohren; Wei Wei; Mohammad A Quraishi; Osama Mawlawi; Thomas A Buchholz; Wei Yang Journal: Acad Radiol Date: 2012-02-01 Impact factor: 3.173
Authors: Maurice P H M Jansen; Leen Sas; Anieta M Sieuwerts; Caroline Van Cauwenberghe; Diana Ramirez-Ardila; Maxime Look; Kirsten Ruigrok-Ritstier; Pascal Finetti; François Bertucci; Mieke M Timmermans; Carolien H M van Deurzen; John W M Martens; Iris Simon; Paul Roepman; Sabine C Linn; Peter van Dam; Marleen Kok; Filip Lardon; Peter B Vermeulen; John A Foekens; Luc Dirix; Els M J J Berns; Steven Van Laere Journal: Mol Oncol Date: 2015-03-04 Impact factor: 6.603
Authors: Steven J Van Laere; Naoto T Ueno; Pascal Finetti; Peter Vermeulen; Anthony Lucci; Fredika M Robertson; Melike Marsan; Takayuki Iwamoto; Savitri Krishnamurthy; Hiroko Masuda; Peter van Dam; Wendy A Woodward; Patrice Viens; Massimo Cristofanilli; Daniel Birnbaum; Luc Dirix; James M Reuben; François Bertucci Journal: Clin Cancer Res Date: 2013-02-08 Impact factor: 12.531
Authors: Massimo Cristofanilli; Stephen R D Johnston; Alexey Manikhas; Henry L Gomez; Oleg Gladkov; Zhimin Shao; Sufia Safina; Kimberly L Blackwell; Ricardo H Alvarez; Stephen D Rubin; Sulabha Ranganathan; Suman Redhu; Maureen E Trudeau Journal: Breast Cancer Res Treat Date: 2012-12-13 Impact factor: 4.872
Authors: Brandon T Nokes; Heather E Cunliffe; Bonnie Lafleur; David W Mount; Robert B Livingston; Bernard W Futscher; Julie E Lang Journal: J Cancer Date: 2013-01-10 Impact factor: 4.207
Authors: I Van der Auwera; S J Van Laere; S M Van den Bosch; G G Van den Eynden; B X Trinh; P A van Dam; C G Colpaert; M van Engeland; E A Van Marck; P B Vermeulen; L Y Dirix Journal: Br J Cancer Date: 2008-10-07 Impact factor: 7.640
Authors: S Van Laere; I Van der Auwera; G Van den Eynden; P Van Hummelen; P van Dam; E Van Marck; P B Vermeulen; L Dirix Journal: Br J Cancer Date: 2007-09-11 Impact factor: 7.640
Authors: Melike Marsan; Gert Van den Eynden; Ridha Limame; Patrick Neven; Jan Hauspy; Peter A Van Dam; Ignace Vergote; Luc Y Dirix; Peter B Vermeulen; Steven J Van Laere Journal: PLoS One Date: 2014-02-21 Impact factor: 3.240